Canada · Delayed Price · Currency is CAD Hydreight Technologies Statistics
Total Valuation
TSXV:NURS has a market cap or net worth of CAD 166.38 million. The enterprise value is 155.20 million.
| Market Cap | 166.38M |
| Enterprise Value | 155.20M |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:NURS has 53.67 million shares outstanding. The number of shares has increased by 23.42% in one year.
| Current Share Class | 53.67M |
| Shares Outstanding | 53.67M |
| Shares Change (YoY) | +23.42% |
| Shares Change (QoQ) | -4.92% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 1.43% |
| Float | 27.34M |
Valuation Ratios
The trailing PE ratio is 24.06 and the forward PE ratio is 6.60.
| PE Ratio | 24.06 |
| Forward PE | 6.60 |
| PS Ratio | 2.12 |
| PB Ratio | 4.22 |
| P/TBV Ratio | 4.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 23.03 |
| EV / Sales | 1.98 |
| EV / EBITDA | 20.22 |
| EV / EBIT | 21.92 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.91, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.91 |
| Quick Ratio | 2.13 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 1.14 |
| Debt / FCF | -0.79 |
| Interest Coverage | 4.61 |
Financial Efficiency
Return on equity (ROE) is 31.44% and return on invested capital (ROIC) is 16.91%.
| Return on Equity (ROE) | 31.44% |
| Return on Assets (ROA) | 11.71% |
| Return on Invested Capital (ROIC) | 16.91% |
| Return on Capital Employed (ROCE) | 14.57% |
| Weighted Average Cost of Capital (WACC) | 8.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 2.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -580,337 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.06% in the last 52 weeks. The beta is 0.64, so TSXV:NURS's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -27.06% |
| 50-Day Moving Average | 3.98 |
| 200-Day Moving Average | 3.88 |
| Relative Strength Index (RSI) | 36.04 |
| Average Volume (20 Days) | 130,379 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TSXV:NURS had revenue of CAD 78.43 million and earned 6.74 million in profits. Earnings per share was 0.13.
| Revenue | 78.43M |
| Gross Profit | 16.09M |
| Operating Income | 7.09M |
| Pretax Income | 6.16M |
| Net Income | 6.74M |
| EBITDA | 7.68M |
| EBIT | 7.09M |
| Earnings Per Share (EPS) | 0.13 |
Balance Sheet
The company has 19.97 million in cash and 8.79 million in debt, with a net cash position of 11.18 million or 0.21 per share.
| Cash & Cash Equivalents | 19.97M |
| Total Debt | 8.79M |
| Net Cash | 11.18M |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 39.45M |
| Book Value Per Share | 0.74 |
| Working Capital | 35.05M |
Cash Flow
In the last 12 months, operating cash flow was -11.10 million and capital expenditures -5,840, giving a free cash flow of -11.11 million.
| Operating Cash Flow | -11.10M |
| Capital Expenditures | -5,840 |
| Depreciation & Amortization | 594,843 |
| Net Borrowing | 10.15M |
| Free Cash Flow | -11.11M |
| FCF Per Share | -0.21 |
Margins
Gross margin is 20.51%, with operating and profit margins of 9.04% and 8.59%.
| Gross Margin | 20.51% |
| Operating Margin | 9.04% |
| Pretax Margin | 7.85% |
| Profit Margin | 8.59% |
| EBITDA Margin | 9.80% |
| EBIT Margin | 9.04% |
| FCF Margin | n/a |
Dividends & Yields
TSXV:NURS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.42% |
| Shareholder Yield | -23.42% |
| Earnings Yield | 4.05% |
| FCF Yield | -6.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for TSXV:NURS is 7.92, which is 155.48% higher than the current price. The consensus rating is "Buy".
| Price Target | 7.92 |
| Price Target Difference | 155.48% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on November 25, 2022. It was a reverse split with a ratio of 0.1546061.
| Last Split Date | Nov 25, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.1546061 |
Scores
TSXV:NURS has an Altman Z-Score of 6.2 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.2 |
| Piotroski F-Score | 3 |